NEW YORK (GenomeWeb News) – Quest Diagnostics today said that it has signed an agreement to offer a non-invasive prenatal test developed by Natera.

The Panorama test uses cell-free fetal DNA in circulating maternal blood to screen for trisomy 21, 18, and 13, as well as monosomy X. It can be used as early as the ninth week of pregnancy, the firms said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.